Altamira Therapeutics Ltd... (CYTO)
NASDAQ: CYTO
· Real-Time Price · USD
0.30
0.00 (0.00%)
At close: Jan 16, 2025, 10:00 PM
Altamira Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | -353.22K | -260.56K | -167.89K | -167.89K | 290.8K | 145.4K | n/a | 237K | 237K | 237K |
Cost of Revenue | 337.99K | 828.02K | 1.32M | 1.32M | 1.19M | 596.12K | n/a | n/a | n/a | n/a |
Gross Profit | -691.22K | -1.09M | -1.49M | -1.49M | -901.43K | -450.72K | n/a | 237K | 237K | 237K |
Operating Income | -1.79M | -3.7M | -5.62M | -6.04M | -7.3M | -6.32M | -5.34M | -12.28M | -9.32M | -7.3M |
Interest Income | 679.86K | 868.02K | 790.08K | 836.22K | 576.2K | 474.01K | 371.82K | 179.47K | 238.33K | 153.68K |
Pretax Income | -15.79M | -17.22M | -18.66M | -12.78M | -8.33M | -7.57M | -6.81M | -14.68M | -12.32M | -10.27M |
Net Income | -15.83M | -17.24M | -18.65M | -12.63M | -8.17M | -7.43M | -6.69M | -14.68M | -12.3M | -10.25M |
Selling & General & Admin | 4.95M | 5.89M | 6.83M | 6.19M | 6.96M | 6.39M | 5.82M | 5.3M | 4.17M | 3.4M |
Research & Development | 13.32M | 13.97M | 14.62M | 14.3M | 8.72M | 8.64M | 8.55M | 6.87M | 5.37M | 4.12M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -215.72K | -215.72K | -215.72K |
Operating Expenses | 14.15M | 15.27M | 16.38M | 20.65M | 17.04M | 16.83M | 16.62M | 14.43M | 12.01M | 10.05M |
Interest Expense | 584.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 2.53M | 3.52M | 4.5M | 3.23M | 3.6M | 2.79M | 1.98M | 1.06M | 615.66K | 355.66K |
Cost & Expenses | 14.49M | 16.09M | 17.7M | 21.97M | 18.23M | 17.43M | 16.62M | 14.43M | 12.01M | 10.05M |
Income Tax Expense | 48.76K | 66.51K | 84.25K | 187.4K | 185.65K | 167.93K | 150.21K | 32.09K | 21.28K | 21.28K |
Shares Outstanding (Basic) | 209.96K | 209K | 277.08K | 48.09K | 38.74K | 38.74K | 31.65K | 34.36K | 31.14K | 31.14K |
Shares Outstanding (Diluted) | 209.96K | 209.96K | 277.08K | 4.53K | 38.74K | 38.74K | 660.00 | 1.32K | 31.14K | 31.14K |
EPS (Basic) | -228.63 | -322.04 | -415.39 | -247.61 | -197.67 | -199.82 | -201.97 | -515.77 | -514.76 | -522.25 |
EPS (Diluted) | -2.15K | -2.25K | -2.34K | 5.57K | 3.79K | 3.79K | 3.78K | -4.27K | -514.76 | -522.25 |
EBITDA | 2.02M | -1.77M | -5.57M | -6.02M | -7.28M | -6.29M | -5.29M | -12.24M | -9.29M | -7.28M |
EBIT | -2.12M | n/a | n/a | n/a | n/a | n/a | n/a | -3.13M | -3.13M | -3.13M |
Depreciation & Amortization | 4.63M | 2.34M | 46.63K | 12.16K | 23.44K | 35.04K | 46.63K | 39.03K | 31.43K | 25.73K |